611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
First Clinical Studies Find Wuhan Virus Closely Resembles SARSA Flu Shot May Spare Your Young Child a Hospital VisitMany of America's Most Critical Workers Are Short on Their ZzzsFaulty Immune System May Lead to Lung CancerOnly 1 in 4 Older Cardiac Patients Get Rehab TherapyPrescription-Strength Steroid Creams Sold Over-the-Counter Can Be DangerousWhat You Need to Know Now About the Wuhan VirusThe Damage of Vaccine MisinformationAHA News: What's Blood Type Got to Do With Clot Risk?Racism Linked to Faster Aging Among BlacksScientists Trace Coronavirus Outbreak to SnakesBlacks, Hispanics More Likely to Have Better Outcome After 'Bleeding' StrokeNew Drug Could Help Stop Blindness From Thyroid Eye Disease'Yo-Yo' Blood Pressure Numbers in Youth a Bad Sign for Health LaterFlame Retardants, Pesticides Remain Threat to U.S. Health: StudyDon't Want a 2nd Heart Attack? Lose the Belly FatHow to Keep Those Blood Vessels PumpingScreening for Chinese Coronavirus to Start at 3 Major Airports: CDCDo You Take Warfarin? Time of Day Might Not MatterHealth Tip: Signs of Food PoisoningSepsis Causes Far More Deaths Worldwide Than ThoughtMillennials Most Likely to Skip Flu Shot, Believe 'Anti-Vaxxer' Claims: PollResearchers Alter Mosquitoes to Resist Dengue InfectionMany Americans Are Inactive, With Southerners Faring WorseVirtual Reality Can Bring Real-Life PainAre Doctors Discarding 'Injured' Kidneys That Might Be Used for Transplant?Nerve Stimulation Therapy Could Cut Fibromyalgia PainWhich Obesity Surgery Is Right for You?Brake Dust Another Driver of Air PollutionWhat Works Best to Help Men With Overactive Bladder?More Studies Link Vaping to Asthma, COPDCertain Diabetes Meds May Lower Gout Risk, TooHeart Transplants From Donors With Hepatitis C May Be Safe: StudyClimate Change May Translate Into More Fatal InjuriesAll in the Timing: Many Get Knee Replacement Too Late or Too SoonHealth Tip: Preparing for an UltrasoundLow Levels of Key Blood Cells Could Signal Higher Death RiskGyms Are Fertile Ground for GermsTwo More Heartburn Meds Recalled Due to Possible CarcinogenZika Damage Showing Up in Babies Deemed 'Normal' at BirthHealth Tip: Coping With Winter NosebleedsHeart Disease May Up Risk of Kidney FailureFlu Cases Surge Early, Could a Tough Season Lie Ahead?Cluster of Unhealthy Risk Factors Could Raise Odds of Recurrent Blood ClotsAHA News: Worried About Dementia? Check This Blood Pressure NumberNew Study Reports Alarming Surge in E-Scooter AccidentsSo Long, 98.6: Average Human Body Temperature Is DroppingWhat Matters More for Obesity Risk, Genes or Lifestyle?Health Tip: Protect Yourself From Household ChemicalsOzone, Wood Smoke Raise Odds of COPD in Smokers and Nonsmokers
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Obesity Might Weaken Some Drugs' Effectiveness Against AFib

HealthDay News
by -- Steven Reinberg
Updated: Dec 2nd 2019

new article illustration

WEDNESDAY, Nov. 27, 2019 (HealthDay News) -- Millions of Americans have the potentially dangerous irregular heartbeat known as atrial fibrillation.

Now, research suggests that being obese might undercut the effectiveness of certain drugs meant to treat AFib.

The new study followed more than 300 patients listed in the University of Illinois at Chicago's AFib Registry. Researchers found that a class of medicines called sodium channel blockers, which are often used to treat AFib, were less effective in obese patients.

In fact, the recurrence rate for the heart arrhythmia was 30% for obese patients taking sodium channel blockers, compared with 6% for non-obese patients.

That could be bad news for many patients, since obesity is a big risk factor for AFib, said a team led by Dr. Dawood Darbar, head of cardiology at the university's College of Medicine.

Still, obese patients may have a viable option: Darbar's team found that another class of drugs, called potassium channel blockers, worked better in obese patients.

"This is the first time anyone has shown that there is a differential response to anti-arrhythmic drugs for AFib," Darbar said in a university news release. "As 50% of the patients in our AFib Registry are obese, this provided us with a unique opportunity to determine whether obesity affected response to drug treatment."

Dr. Satjit Bhusri, a cardiologist at Lenox Hill Hospital in New York City, said the new findings make sense, given what's known about how sodium channel blockers work.

"Most antiarrhythmic drugs distribute throughout the body and are absorbed by many organs," explained Bhusri, who wasn't involved in the Chicago study. "Since these drugs require a large dose to reach a steady level in the blood, those patients that are obese may well be under-treated -- they may require increased dosing compared to thinner patients."

But upping the dose could lead to unwanted side effects, he added, so doctors may want to consider other treatment options in obese patients.

According to Bhusri, sodium channel blockers commonly prescribed for AFib include quinidine, procainamide, felcianide and propafenone.

Darbar agreed that the new study offers obese patients a route to better treatment.

The obesity epidemic is increasing, he said, so "having treatment options to better manage AFib would greatly improve quality of life and could prevent the risk of serious complications, like stroke, which can cause early death."

Dr. Laurence Epstein is system director of electrophysiology at Northwell Health in Manhasset, N.Y. Reading over the new findings, he agreed that "treating atrial fibrillation remains a challenge."

"What we are learning is that all AFib is not the same," he said. "If you asked an oncologist how do you treat cancer, they would ask you, what type of cancer? The same is true for AFib. The present study adds additional support to the notion that all AFib is not the same, and we need to be tailoring treatment to individual patients."

The study was published online Nov. 27 in the journal JAMA Cardiology.

More information

The U.S. National Heart, Lung, and Blood Institute has more on atrial fibrillation.